Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma
Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma
复制标题
DOI：
10.1111/j.1600-0609.2006.00679.x
复制
发表时间：
2006-08-01
影响因子：
3.1
通讯作者：
Schmetzer, H. M.
中科院分区：
文献类型：
--
作者：
Hentschel, N.;Krusch, M.;Schmetzer, H. M.
CD178（Fas/APO-1配体）和CD137配体（CD137L）先前已在各种恶性肿瘤患者的血清中被描述，并且在各种疾病的发病机制中发挥重要作用。最近，我们证明低水平的可溶性 CD137L 和高水平的 sCD178 与骨髓增生异常综合征 (MDS) 患者的长期无进展生存期显着相关。在这项研究中，我们将 42 例急性髓系白血病 (AML) 患者样本和 46 例非霍奇金淋巴瘤 (NHL) 患者样本的血清中 sCD137L 和 sCD178 水平与疾病的分期、亚型和临床病程相关联，并确定了具有最大概率的临界值，以显着区分无进展生存概率较高/较低的病例。与 MDS 患者相反，令人惊讶的是，sCD178 水平与不同亚型和阶段或 AML 或 NHL 预后之间没有相关性。与 AML 相比，NHL 患者的 sCD137L 水平较低。与单核细胞样 AML（M4/M5，89 pg/mL）、中等细胞遗传学风险（59 pg/mL）和较低水平的患者相比，未分化 AML（M1/M2，1470 pg/mL）、低细胞遗传学风险（288 pg/mL）和较高水平 BM 母细胞（186 pg/mL）的患者中 sCD137L 中位水平具有统计学意义（统计学意义）分别为 BM 母细胞 (14 pg/mL)。此外，在 AML 患者中，sCD137L 水平与实现完全缓解 (CR)、保持 CR 或疾病进展的概率显着相关。综上所述，我们的数据表明 sCD137L 不仅可以用作 MDS 的预后因素，也可以用作 AML 的预后因素。
CD178 (Fas/APO-1 ligand) and CD137 ligand (CD137L) have previously been described in sera of patients with various malignancies and play an important role in the pathogenesis of various diseases. Recently, we demonstrated that low levels of soluble (s) CD137L and high levels of sCD178 correlate significantly with a long progression free survival in patients with myelodysplastic syndrome (MDS). In this study, we correlated sCD137L and sCD178 levels in sera of 42 samples of patients with acute myeloid leukemia (AML) and 46 samples of patients with non-Hodgkin's lymphoma (NHL) with stages, subtypes, and the clinical course of the diseases and determined cut-off values with maximum probability for significant differentiation between cases with higher/lower probability for progress free survival. In contrast to patients with MDS, surprisingly no correlation between sCD178 levels and different subtypes and stages or with prognosis in AML or NHL were observed. Regarding sCD137L, NHL-patients displayed lower levels compared with AML. Statistically significant higher median levels of sCD137L are present in patients with undifferentiated AML (M1/M2, 1470 pg/mL), poor cytogenetic risk (288 pg/mL) and higher levels of BM-blasts (186 pg/mL) compared with patients with monocytoid AML (M4/M5, 89 pg/mL), intermediate cytogenetic risk (59 pg/mL) and lower levels of BM-blasts (14 pg/mL) respectively. Furthermore, in AML patients sCD137L levels correlate significantly with the probabilities to achieve complete remission (CR), stay in CR or with progress of the disease. Taken together, our data demonstrate that sCD137L can be used as a prognostic factor not only in MDS but also in AML.